News & Updates

Show Multimedia Only

Double-dose tigecycline more effective than standard doses, but with potentially more side effects

06 Aug 2022

Twice-daily 100-mg doses of tigecycline leads to better clinical response, bacterial clearance, and survival in intensive care unit patients with ventilator-associated pneumonia, reports a recent meta-analysis. However, such a double-dose regimen may also show higher treatment toxicities.

06 Aug 2022

Is bevacizumab beneficial for patients undergoing high-risk corneal transplantation?

06 Aug 2022

Treatment with bevacizumab in patients undergoing vascularized high-risk corneal transplantation shows no significant difference in the rate of endothelial rejection at 1 year when compared to placebo, reports a recent study.

06 Aug 2022

Oxcarbazepine exposure during pregnancy ups risk of malformations, foetal death

05 Aug 2022

Exposure to oxcarbazepine during pregnancy is associated with congenital malformations and even foetal/perinatal death, suggest the results of a systematic review and meta-analysis.

05 Aug 2022

RATIONALE-208 subanalyses boost tislelizumab potential for HCC

05 Aug 2022 by

The monoclonal antibody tislelizumab continued to show promise as a treatment alternative in certain subgroups of patients with previously treated advanced hepatocellular carcinoma (HCC), according to subgroup analyses of the phase II, single-arm RATIONALE-208 study.

05 Aug 2022

Expectant mums’ use of dolutegravir safe for babies

04 Aug 2022 by

Treatment with dolutegravir during pregnancy does not appear to pose an excess risk of adverse birth outcomes, according to two studies presented at the 24th International AIDS Conference in Montreal, Canada.

04 Aug 2022

Abiraterone-olaparib confers clinical benefit for mCRPC patients

04 Aug 2022 by

The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.

04 Aug 2022

Dexamethasone eye drops show therapeutic potential in diabetic macular edema

04 Aug 2022

Topical OCS-01, a dexamethasone ophthalmic suspension, appears to be beneficial in the treatment of patients with diabetic macular edema, with the results of a phase II study showing that the drug helps improve central macular thickness.

04 Aug 2022

FLASH: Light-activated hypericin ointment gets high marks in early-stage mycosis fungoides

03 Aug 2022 by

Photodynamic therapy using topically applied hypericin 0.25% is effective against early-stage patch and plaque lesions in patients with mycosis fungoides−cutaneous T-cell lymphoma, while having a favourable safety profile, as shown in the phase III FLASH trial.

03 Aug 2022